A Phase 1 interventional study of BHV-1300 in Graves Disease, sponsored by Biohaven Therapeutics Ltd.. Recruiting at 18 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-31.
Sponsored by Biohaven Therapeutics Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Graves Disease with a site in United States — 16 open to participants now, 18 under way, 3 of them phase 3. Graves Disease · United States.
Among the 43 studies in Graves Disease with a site in United States, this one is the 28th largest by planned enrollment of the 33 interventional ones that give a count, is one of 4 that started in 2025, is one of 3 in phase 1, reaches primary completion later than 8 of the 17 other live ones, and was the 31st registered.
162 studies on the registry are indexed under Graves Disease; 53 are open to participants now.
Browse Graves Disease studies →16 of the 43 studies in Graves Disease with a site in United States are open now. Recruiting first, the newest first:
Sling Therapeutics, Inc. · Sites in United States
Ages 18+
Biogen · Sites in United States, Puerto Rico
Ages 18–75
Appalachian State University · Sites in United States
Ages 18–65
Ethyreal Bio, Inc. · Sites in United States
Ages 18+ · Healthy volunteers
Biohaven Therapeutics Ltd. · Sites in United States, Canada, Puerto Rico
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 39 Graves Disease studies recruiting now, 17 (44%) set no upper age limit and 20 (51%) stop at 75 or younger; 3 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 13 · Phase 3 10 · Phase 4 4
First in 1993; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 15 is below the median of 60 across 104 interventional studies indexed under Graves Disease.
Median enrollment 76 across the 33 interventional studies, 42 across the 10 observational. Of the 21 that completed or were terminated, 11 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 43 have an industry lead sponsor. The 10 most frequent:
Biohaven Therapeutics Ltd. is the lead sponsor of 20 studies on the registry; 9 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Biohaven Therapeutics Ltd. has 3 studies filed under Graves Disease — fewer than ten, so there is no comparison to draw.
4 of the studies in Graves Disease with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05435547Indiana UniversityPreoperative Corticosteroids in Autoimmune Thyroid Disease | 2026-12-30 |
| NCT07413874Appalachian State UniversityTelehealth Music Therapy for Adults With Endocrine Disorder and Depression | 2026-12-31 |
| NCT07018323Immunovant Sciences GmbHA Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease | 2027-05 |
| NCT06980649Biohaven Therapeutics Ltd.Study of BHV-1300 in Graves' Disease | 2027-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 43 studies in Graves Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if BHV-1300 is a safe treatment in participants with Graves' Disease and to explore its effect on disease-specific biomarkers.
Key Inclusion Criteria:
1. Participants must have serologically confirmed Graves' Disease.
Key Exclusion Criteria:
Drug: BHV-1300
BHV-1300 is delivered subcutaneously (SC)
Number of participants with Serious AEs (SAEs), AEs leading to discontinuation, deaths
To assess the safety and tolerability of BHV-1300. This objective will be measured by assessing the number of unique subjects with SAEs, AEs leading to discontinuation or deaths that are observed during the Open-label Treatment Phase (up to 52 weeks).
Time frame: Baseline to Week 52
Number of participants with Grade 3-4 (CTCAE/DAIDS) treatment-emergent laboratory abnormalities
To assess the safety and tolerability of BHV-1300. This objective will be measured by assessing the number of unique subjects with Grade 3 or 4 treatment-emergent laboratory abnormalities.
Time frame: Baseline to Week 52
Started Aug 2025 (actual). Primary completion is estimated for Sep 2027, 25 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: BHV-1300
Biohaven Therapeutics Ltd.